We incorporated six additional GLP‐1 RA‐based drugs (efpeglenatide, orforglipron, retatrutide, etc.), allowing for a more comprehensive assessment of the cardiovascular protective effects of GLP‐1RA‐based therapies in obese or overweight patients without diabetes. Here, GLP1R is linked to diabetes mellitus.